Category: Multiple Myeloma

Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma

Continuing carfilzomib therapy beyond its known long-term safety limits may provide additional clinical benefit to patients with relapsed multiple myeloma (MM), according to a study published the Journal of Hematology and Oncology.

Results of the ASPIRE trial demonstrated that carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and complete response (CR) rates compared with lenalidomide plus dexamethasone (Rd) alone among patients with relapsed MM. However, carfilzomib was discontinued after 18 treatment cycles due to a lack of long-term safety data and patients continued on Rd alone, leaving the benefit/risk profile of KRd to progression unknown.


Multiple Myeloma Combination Therapy

In a recent study, a combination therapy for the treatment of relapsed or refractory multiple myeloma proved to be as beneficial in routine clinical practice as it did in clinical trials used to support its approval.

Lenalidomide has demonstrated significant clinical activity against relapsed and refractory multiple. The phase III trials MM-009 and MM-010 have been used as supporting evidence for the US Food and Drug Administration approval of lenalidomide plus dexamethasone to treat patients with multiple myeloma who have received at least one prior therapy. Additionally, lenalidomide monotherapy is approved in the first-line setting for patients with multiple myeloma.

A group of German researchers at the Agaplesion Bethanien Hospital analyzed the effects of lenalidomide plus dexamethasone in 98 patients who were treated in routine clinical practice. Patients in the non-interventional study had a median age of 71 years, which was higher than the median ages of the phase III trials (64 and 63 years, respectively). A total of 47 patients in the non-interventional study received the combination therapy in the second-line setting, while 51 patients received it as a third-line or higher therapy.


Lenalid (Generic of Revlimid)

Lenalidomide is to improve the survival and quality of life of the cancer patients.

Packing of Lenalid-
Lenalid is accessible as 5mg, 10mg, 15mg & 25mg (30 tablets/bottle).

The Indian Pharma is one of the largest online consultancy company based in Delhi-NCR (India). We connect the patients across the globe to validated pharmaceutical distributors in India.

We provide the Lenalid (Generic of Revlimid) at the best price in India and Every week we have been serving many patients from various countries in Eastern and Southeastern Europe and Brazil, Venezuela & SE Asia including China and South East Asia.

You can Buy anti-cancer drugs and their generics from our Indian generic which is one of the best online consulting company in Delhi, India. who easily provides not only anti-cancer medicines but also offer the all types of medicines at cheapest and affordable prices at our website- and also contact through phone/WhatsApp and Mail- +91 8130290915 ,